Three Motley Fool contributors believe they've found no-brainer healthcare stocks to buy in June. (Amgen): One of the best ...

Barreling toward the loss of exclusivity on its blockbuster oncology therapy Keytruda, Merck & Co. has reportedly offered $3 ...

An experimental COPD drug from Sanofi and Regeneron showed mixed results in a pair of studies, sending the companies' shares ...

Amgen said interim results from a Phase 3 trial showed Imdelltra reduced the risk of death and other benefits for patients with small cell lung cancer.

H.C. Wainwright reiterated its Buy rating and $28 price target for Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) on May 29, ...

Zai Lab Limited (NASDAQ:ZLAB) and NovoCure Limited (NASDAQ:NVCR) revealed landmark results from the Phase 3 PANOVA-3 trial at ...

In its first global phase 3 readout, Akeso and Summit Therapeutics’ closely watched PD-1xVEGF bispecific antibody ivonescimab ...

MCU Phase 3 raised the bar in every possible way. The fights looked better. The stakes felt heavier. The damage hit harder.

The San Francisco 49ers are starting the final phase of their offseason program, and while it's not the same as training camp ...

Drug makers Spero Therapeutics and GSK announced yesterday that a phase 3 trial evaluating their investigational oral ...

Swiss drugmaker Roche said on Monday it would advance testing of an antibiotic against a common drug-resistant bacteria that ...